Novavax Q2 revenue $239M; net income $107M; $175M Sanofi milestone from FDA BLA approval

NOVAVAX INC

2025-Q2 EPS reported $3.55 revenue$905,895,000

Total revenue of $239M, down 42% YoY, includes $175M milestone from Nuvaxovid BLA approval.
Net income of $107M vs $162M YoY; cash $628M; $175M milestone receipt expected Q3 2025.
Updated FY2025 adjusted total revenue guidance to $1,000-1,050M (prior $975-1,025M).
Combined R&D/SG&A expense guidance raised to $495-545M; includes $20M postmarketing study cost.
Phase 3 data for COVID-flu combo and standalone flu candidates showed robust immune responses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.